CRYO CELL INTERNATIONAL INC reported second-quarter 2026 revenue of $7.78M, down from $7.93M in the year-ago quarter, and revenue of $15.46M for the six months ended May 31, 2026, down from $15.9M in the prior-year six-month period.
Financial Highlights
- Revenue: $7.78M for Q2 FY2026, down from $7.93M in Q2 FY2025 ( (2%) YoY).
- Revenue: $15.46M for the six months ended May 31, 2026, down from $15.90M in the prior-year six months ((2.8%) YoY).
Business Highlights
- Processing and storage revenue for the six-month period was $15.36M, driven lower by fewer new domestic specimens despite higher recurring fees.
- Customer acquisition continues to rely on direct-to-parent marketing and clinical referrals; strong repeat and referral enrollments support the recurring storage base.
- Product and service expansion included the launch of a cord tissue service and ExtraVault, a third-party cold storage offering targeting biopharma and healthcare customers.
- Operations include a cGMP/cGTP AABB/FACT‑accredited facility in Oldsmar and a 56,000 sq ft Durham site for expanded storage, processing and potential cell therapy work.
- A planned clinic, biopharma manufacturing activities and the Celle Corp. spinoff have been paused due to a Duke license dispute, delaying related investments and timelines.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.